velaglucerase alfa velaglucerase alfa velaglucerase alfa, sold under the brand name vpriv, is a medication used for the treatment of gaucher disease type 1. it is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. it has an identical amino acid sequence to the naturally occurring enzyme. it is manufactured by shire plc. velaglucerase alfaclinical datatrade namesvprivahfs/drugs.commonographlicense data eu ema: by inn us dailymed: velaglucerase alfa routes ofadministrationintravenousatc codea16ab10 (who) legal statuslegal status au: s4 (prescription only) us: ℞-only eu: rx-only in general: ℞ (prescription only) pharmacokinetic databioavailabilityn/aelimination half-lifeplasma: 5–12 minutes (absorbed by macrophages)identifierscas number884604-91-5 ydrugbankdb06720 ychemspidernoneunii23hye36b0ikeggd09029chemblchembl1201865 nchemical and physical dataformulac2532h3850n672o711s16molar mass55593.61 g·mol−1 ny (what is this?) (verify) the most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature. velaglucerase alfa was approved for medical use in the united states in february 2010, and in the european union in august 2010. medical uses velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ert) in people with type-1 gaucher disease.